De
Dermavant Sciences
Basel CHFounded 2016120 employees
Private CapbiotechPrivateDermatology
Platform: Tapinarof Derm
Market Cap
N/A
All Drugs
4
Clinical Trials
8
Failed / Terminated
1
FDA Approved
0
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Doxasacituzumab | DER-8206 | Phase 1 | 2 | SGLT2 | GBM | ||
| Fixazasiran | DER-2786 | Phase 2/3 | 2 | PD-L1 | RAFTD | ||
| DER-8696 | DER-8696 | Phase 1/2 | 2 | EGFR | Gastric CaNSCLC | ||
| Riboosocimab | DER-5098 | Phase 2 | 2 | CD3 | Atopic DermCholangiocarcinoma |
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (8)